How can pharmaceutical companies uncover new value from existing therapies without the cost and risk of developing new drugs from scratch?
In this case study, discover how a leading pharmaceutical organization partnered with Phastar to apply AI and real-world evidence (RWE) to identify promising new indications for approved therapies in multiple sclerosis and related autoimmune diseases.
Using millions of longitudinal patient records across the US and Europe, the team developed a scalable, data-driven approach to drug repurposing that accelerated insight generation and supported better strategic decision-making.
Download the case study to learn how:
- AI was used to identify new therapeutic opportunities at scale
- Real-world data revealed previously unseen treatment outcomes
- Discovery timelines were accelerated
- Existing drug assets delivered greater value and commercial potential
- Data-driven insights reduced development risk and improved confidence
Download the full case study, by completing the form below, to see how AI and biometrics expertise can help unlock new opportunities across your drug portfolio.
